Fwd: Low phosphorylation of ER{alpha} serine 118 and high phosphorylation of ER{alpha} serine 167 improve survival in ER-positive breast cancer.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sun, Jun 15, 2008 at 11:30 AM
Subject: Low phosphorylation of ER{alpha} serine 118 and high phosphorylation of ER{alpha} serine 167 improve survival in ER-positive breast cancer.
To: mesothelioma77@gmail.com


[1]Endocr Relat Cancer. 2008 Jun 12;
Yamashita H, Nishio M, Toyama T, Sugiura H, Kondo N, Kobayashi S, Fujii Y, Iwase H

Endocrine therapy has become the most important treatment option for women with estrogen receptor (ER)-positive breast cancer. Urgently needed are prognostic assays that can identify those who need additional adjuvant therapy, such as signal transduction inhibitors or chemotherapy, for ER-positive early breast cancer. We examined phosphorylation of ERalpha serine (Ser) 118, ERalpha Ser167, p44/42 MAPK and Akt, and expression of progesterone receptor (PR), AIB1, HER2, p53 and Ki67 in ER-positive breast cancers by immunohistochemistry, and analyzed their significance for prognosis. Phosphorylation levels of ERalpha Ser118, ERalpha Ser167, MAPK and Akt were positively correlated. AIB1 expression was significantly associated with phosphorylation of ERalpha Ser118, MAPK and Akt, and HER2 expression. Low phosphorylation of ERalpha Ser118 and high phosphorylation of ERalpha Ser167 were associated with significantly improved disease-free (P = 0.0003 and P = 0.0002, respectively) and overall survival (P = 0.0007 and P = 0.0016, respectively) in multivariate analyses. Our data suggest that phosphorylation of ERalpha Ser118 and ERalpha Ser167 affects survival in ER-positive breast cancer and could be helpful in distinguishing patients who are likely to benefit from endocrine therapy alone from those who are not.



___
Source: http://www.hubmed.org/display.cgi?uids=18550720
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Axillary recurrence in sentinel lymph node-negative breast cancer patients.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sun, Jun 15, 2008 at 11:30 AM
Subject: Axillary recurrence in sentinel lymph node-negative breast cancer patients.
To: mesothelioma77@gmail.com


[1]Ann Oncol. 2008 Jun 10;
Poletti P, Fenaroli P, Milesi A, Paludetti A, Mangiarotti S, Virotta G, Candiago E, Bettini A, Caremoli ER, Labianca R, Tondini C

BACKGROUND: Sentinel lymph node biopsy (SLNB) was developed to axillary lymph node dissection (ALND) in the treatment of breast cancer. SLNB is predictive of axillary node status. Major concern is the occurrence of a false-negative SLN. Purpose of this study is to determine the rate of axillary recurrence in our series of unselected patients. PATIENTS AND METHODS: All patients with a negative SLNB from November 1999 to December 2006 have been treated and followed at our unit. Information on patients' characteristics, treatment and follow-up has been collected. RESULTS: Eight-hundred and four patients with negative SLNB did not receive ALND. After a median follow-up of 38.8 months, 21 patients had distant metastases, four had axillary relapse, nine had an in-breast recurrence and two had both. All patients with axillary recurrence received axillary dissection and systemic adjuvant therapy. They are all presently alive and free from disease. CONCLUSION: Data from this series, the largest from a general hospital, showed that isolated axillary node recurrence after negative SLNB is rare (

___
Source: http://www.hubmed.org/display.cgi?uids=18550574
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc